GENB — Generate Biomedicines, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2100782 ·
Last close
$9.84
Market Cap
$1.27B
52W High
$22.67
52W Low
$9.73
ADV30
976,158
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 4,220,000 | — | -91,507,000 | -87,657,000 | 515,890,000 | 140,350,000 | 134,734,000 |
| Jun 2026 | 6,314,000 | — | -71,614,000 | -67,255,000 | 561,690,000 | 135,359,000 | 105,645,000 |
| Mar 2026 | 7,224,000 | — | -64,112,000 | -61,446,000 | 625,737,000 | 160,575,000 | 110,936,000 |
| Dec 2025 | 3,311,000 | — | -63,949,000 | -55,425,000 | 330,182,000 | 121,650,000 | 953,379,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-240,261,000
Investing CF
$-168,159,000
Financing CF
$398,609,000
CapEx
$-5,619,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.74
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-804,994,000
Inventory
—
Receivables
—
ST Investments
$322,056,000
EBIT TTM
$-228,832,000
Pretax Income TTM
$-229,844,000
Interest Exp TTM
$1,012,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$21,069,000
EBITDA
$-277,863,008
Free Cash Flow
—
Enterprise Value
$1,229,325,696
Total Cash
$404,212,000
Total Debt
$75,341,000
Shares Out
129,096,666
Trailing EPS
$-2.44
Book Value
$2.95
ROE
—
ROA
—
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 31,893,000 | -235,065,000 | -203,154,000 | 330,182,000 | 953,379,000 | -615,965,000 | -200,619,000 |
| Dec 2024 | 20,459,000 | -196,939,000 | -173,771,000 | 518,259,000 | 953,349,000 | -434,519,000 | -117,750,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$561,690,000
Forward EPS
$-2.38
Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $12.50 · spot: $10.38 · call volume: 73 · put volume: 11
Expected Move to 2027-04-16:
±$4.22
(40.70%) —
implied range
$6.16 –
$14.61
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MLYS | Mineralys Therapeutics, Inc. | $1.28B | $14.48 | — |
| GHRS | GH Research PLC | $1.25B | $18.27 | — |
| AVLN | Avalyn Pharma Inc. | $1.24B | $27.92 | — |
| AMPH | Amphastar Pharmaceuticals, Inc. | $1.24B | $29.10 | — |
| INVA | Innoviva, Inc. | $1.30B | $18.30 | — |
News headlines (Yahoo Finance, 1h cache)
Generate Biomedicines: Q3 Earnings Snapshot
2026-11-12 12:37 · Yahoo
Generate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-12 12:20 · Yahoo
Generate Biomedicines (GENB) Stock Looks Fully Priced On Its 17% Jump
2026-10-31 06:18 · Yahoo
Generate Biomedicines to Participate in November Investor Conferences
2026-10-22 11:00 · Yahoo
Zealand Pharma pens $1.2bn AI obesity drug discovery pact with Generate
2026-10-14 16:17 · Yahoo
Generate Biomedicines Lands Major AI Drug Partnership to Target Booming Obesity Market
2026-10-14 15:30 · Yahoo
Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
2026-10-13 20:30 · Yahoo
Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
2026-10-13 20:30 · Yahoo
Prologue Medicines Appoints Stephen Harrison, Ph.D., as Chief Scientific Officer
2026-10-13 14:00 · Yahoo
Generate Biomedicines Inc. to Participate in September Investor Conferences
2026-09-08 11:09 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.